Immunovant shareholders elect all three director nominees, ratify auditor, approve say-on-pay

Immunovant, Inc.

Jacob Bauer, Douglas Hughes, and Robert Susman elected to Board until 2026 annual meeting.
Ernst & Young ratified as independent auditor for FY ending March 31, 2026 (165.4M for, 7K against).
Non-binding advisory vote on named executive officer compensation approved (159.0M for, 1.2M against).
Approximately 97% of outstanding shares represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.